Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis
Background Patients undergoing in vitro fertilisation (IVF) receive various adjuvant therapies in order to enhance success rates, but the true benefit is actively debated. Growth hormone (GH) supplementation was assessed in poor-prognosis women undergoing fresh IVF transfer cycles. Methods Data were...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
BMJ Group
2017
|
| Online Access: | http://hdl.handle.net/20.500.11937/57763 |
| _version_ | 1848760091850833920 |
|---|---|
| author | Keane, Kevin Yovich, John Hamidi, Anahita Hinchliffe, P. Dhaliwal, Satvinder S. |
| author_facet | Keane, Kevin Yovich, John Hamidi, Anahita Hinchliffe, P. Dhaliwal, Satvinder S. |
| author_sort | Keane, Kevin |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Background Patients undergoing in vitro fertilisation (IVF) receive various adjuvant therapies in order to enhance success rates, but the true benefit is actively debated. Growth hormone (GH) supplementation was assessed in poor-prognosis women undergoing fresh IVF transfer cycles. Methods Data were retrospectively analysed from 400 IVF cycles, where 161 women received GH and 239 did not. Results Clinical pregnancy, live birth rates and corresponding ORs and CIs were significantly greater with GH, despite patients being significantly older with lower ovarian reserve. Patient's age, quality of transferred embryo and GH were the only significant independent predictors of clinical pregnancy (OR: 0.90, 5.00 and 2.49, p < 0.002, respectively) and live birth chance (OR: 0.91, 3.90 and 4.75, p < 0.014, respectively). GH increased clinical pregnancy chance by 3.42-fold (95% CI 1.82 to 6.44, p < 0.0005) and live birth chance by 6.16-fold (95% CI 2.83 to 13.39, p < 0.0005) after adjustment for maternal age, antral follicle count and transferred embryo quality. Conclusion These data provided further evidence to indicate that GH may support more live births, particularly in younger women. It also appears that embryos generated under GH have a better implantation potential, but whether the biological mechanism is embryo-mediated or endometrium-mediated is unclear. © Article author(s) 2017. |
| first_indexed | 2025-11-14T10:10:16Z |
| format | Journal Article |
| id | curtin-20.500.11937-57763 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:10:16Z |
| publishDate | 2017 |
| publisher | BMJ Group |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-577632018-01-24T03:16:40Z Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis Keane, Kevin Yovich, John Hamidi, Anahita Hinchliffe, P. Dhaliwal, Satvinder S. Background Patients undergoing in vitro fertilisation (IVF) receive various adjuvant therapies in order to enhance success rates, but the true benefit is actively debated. Growth hormone (GH) supplementation was assessed in poor-prognosis women undergoing fresh IVF transfer cycles. Methods Data were retrospectively analysed from 400 IVF cycles, where 161 women received GH and 239 did not. Results Clinical pregnancy, live birth rates and corresponding ORs and CIs were significantly greater with GH, despite patients being significantly older with lower ovarian reserve. Patient's age, quality of transferred embryo and GH were the only significant independent predictors of clinical pregnancy (OR: 0.90, 5.00 and 2.49, p < 0.002, respectively) and live birth chance (OR: 0.91, 3.90 and 4.75, p < 0.014, respectively). GH increased clinical pregnancy chance by 3.42-fold (95% CI 1.82 to 6.44, p < 0.0005) and live birth chance by 6.16-fold (95% CI 2.83 to 13.39, p < 0.0005) after adjustment for maternal age, antral follicle count and transferred embryo quality. Conclusion These data provided further evidence to indicate that GH may support more live births, particularly in younger women. It also appears that embryos generated under GH have a better implantation potential, but whether the biological mechanism is embryo-mediated or endometrium-mediated is unclear. © Article author(s) 2017. 2017 Journal Article http://hdl.handle.net/20.500.11937/57763 10.1136/bmjopen-2017-018107 http://creativecommons.org/licenses/by-nc/4.0/ BMJ Group fulltext |
| spellingShingle | Keane, Kevin Yovich, John Hamidi, Anahita Hinchliffe, P. Dhaliwal, Satvinder S. Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis |
| title | Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis |
| title_full | Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis |
| title_fullStr | Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis |
| title_full_unstemmed | Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis |
| title_short | Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis |
| title_sort | single-centre retrospective analysis of growth hormone supplementation in ivf patients classified as poor-prognosis |
| url | http://hdl.handle.net/20.500.11937/57763 |